SAN
DIEGO, June 24, 2024 /PRNewswire/ -- Healcisio, a
leader in AI and digital healthcare, announces it has received a
$1 Million STTR Phase II award from
the NIAID to advance the development of its critical care decision
support platform and a new AI-powered software suite for
abstracting and reporting quality measures.
In what is still one of the country's only peer reviewed,
prospective implementation studies for sepsis AI, Healcisio
previously demonstrated a remarkable reduction in sepsis mortality
by 17% and an improvement in SEP-1 bundle compliance by nearly 10%.
In the coming year Healcisio will begin expanding this work to two
additional health systems and deploying new generative AI tools
related to quality assessment for the in-hospital care of sepsis
patients.
"Predictive analytics is an increasingly important part of the
healthcare delivery process; however, it's only one factor in a
highly complex system. Maturing how we measure quality and making
it efficient is long overdue and can profoundly benefit patients
and providers. We think Healcisio's holistic approach to this
problem will drive meaningful change for the treatment of sepsis
and many other complex medical conditions," said Aaron Boussina, Healcisio CEO.
Currently all hospitals that receive CMS funding have a
requirement to self-report a host of quality measures related to
the care they deliver. Within US physician practices, the annual
cost of quality reporting has been reported as 785 hours per
physician and over $15 billion. One
of the most debated and time consuming measures is related to
sepsis and is called SEP-1. The SEP-1 measure requires significant
manual abstraction and time to complete. Using the latest
advances in Large Language Models (LLMs), Healcisio has developed a
number of quality measure automation tools, including an LLM-based
system that ingests patient charts, via Fast Healthcare
Interoperability Resources (FHIR), and outputs a completed Severe
Sepsis and Septic Shock (SEP-1) abstraction.
As part of the multi-site deployment of its sepsis AI model,
Healcisio will be partnering with quality improvement stakeholders
with the hope of alleviating the clinical workload associated with
manual chart reviews, thereby reallocating precious clinician time
to enhance care quality initiatives at the patients' bedside.
About Healcisio, Inc.
Healcisio, Inc. is a healthcare technology startup based in
La Jolla, CA, focused on bringing
state-of-the-art AI-based diagnostic tools to the bedside.
This content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institutes of Health.
Media Contact:
team@healcisio.com
View original
content:https://www.prnewswire.com/news-releases/healcisio-receives-phase-ii-sttr-funding-to-continue-critical-care-ai-research-302180027.html
SOURCE Healcisio